Justin I. Odegaard
0000-0001-9957-2962
Publication & Citation Trends
Publications
0 total
Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden (pTMB): Results from a SCRUM-Japan GOZILA phase II trial.
Cited by 0
Semantic Scholar
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer
Cited by 24
Semantic Scholar
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. OA
Cited by 8
Semantic Scholar
Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).
Cited by 15
Semantic Scholar
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes
Cited by 14
Semantic Scholar
Efficacy and safety of futibatinib for refractory advanced solid malignancies with FGFR alterations identified in circulating tumor DNA: TiFFANY, A GOZILA-affiliated Trial.
Cited by 3
Semantic Scholar
Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy OA
Cited by 3
Semantic Scholar
Abstract P1-18-07: Impact of PIK3CA mutation (PIK3CA-mt) clonality on alpelisib (ALP) activity based on real-world evidence (RWE) following liquid biopsy testing
Cited by 0
Semantic Scholar
Research Topics
Cancer Genomics and Diagnostics
(147)
Lung Cancer Treatments and Mutations
(57)
Genetic factors in colorectal cancer
(55)
Colorectal Cancer Treatments and Studies
(38)
Adipokines, Inflammation, and Metabolic Diseases
(17)
Affiliations
Palo Alto University
University of California, San Francisco
IDEO (United States)
Stratford University
Guardant (United States)